Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma

Objective: We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high-risk cytogenetic abnormalities in lenalidomide-pretreated patients with multiple myeloma at first relapse. Methods: OPTIMISMM was...

Descripción completa

Detalles Bibliográficos
Autores: Richardson, Paul G.|||0000-0002-7426-8865, Schjesvold, Fredrik|||0000-0003-1096-0569, Weisel, Katja, Moreau, Philippe|||0000-0003-1780-8746, Anderson, Larry D., White, Darrell, Rodriguez-Otero, Paula|||0000-0001-5236-7785, Sonneveld, Pieter|||0000-0002-0808-2237, Engelhardt, Monika|||0000-0003-0405-1676, Jenner, Matthew, Corso, Alessandro, Dürig, Jan, Pavic, Michel, Salomo, Morten, Beksac, Meral, Oriol, Albert|||0000-0001-6804-2221, Lindsay, Jindriska, Liberati, Anna Marina, Galli, Mónica, Robak, Pawel, Larocca, Alessandra|||0000-0002-2070-3702, Yagci, Munci, Vural, Filiz, Kanate, Abraham, Jiang, Ruiyun, Grote, Lara, Peluso, Teresa, Dimopoulos, Meletios|||0000-0001-8990-3254
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:289540
Acceso en línea:https://ddd.uab.cat/record/289540
https://dx.doi.org/urn:doi:10.1111/ejh.13706
Access Level:acceso abierto
Palabra clave:Aged
Chromosome aberrations
Multiple myeloma
Pomalidomide
Renal insufficiency
id ES_f7419f0f5fb7157ff009a9b7f2d3bb9c
oai_identifier_str oai:ddd.uab.cat:289540
network_acronym_str ES
network_name_str España
repository_id_str
spelling Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myelomaA subanalysis of OPTIMISMM by clinical characteristicsRichardson, Paul G.|||0000-0002-7426-8865Schjesvold, Fredrik|||0000-0003-1096-0569Weisel, KatjaMoreau, Philippe|||0000-0003-1780-8746Anderson, Larry D.White, DarrellRodriguez-Otero, Paula|||0000-0001-5236-7785Sonneveld, Pieter|||0000-0002-0808-2237Engelhardt, Monika|||0000-0003-0405-1676Jenner, MatthewCorso, AlessandroDürig, JanPavic, MichelSalomo, MortenBeksac, MeralOriol, Albert|||0000-0001-6804-2221Lindsay, JindriskaLiberati, Anna MarinaGalli, MónicaRobak, PawelLarocca, Alessandra|||0000-0002-2070-3702Yagci, MunciVural, FilizKanate, AbrahamJiang, RuiyunGrote, LaraPeluso, TeresaDimopoulos, Meletios|||0000-0001-8990-3254AgedChromosome aberrationsMultiple myelomaPomalidomideRenal insufficiencyObjective: We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high-risk cytogenetic abnormalities in lenalidomide-pretreated patients with multiple myeloma at first relapse. Methods: OPTIMISMM was a phase 3, multicenter, open-label, randomized study (NCT01734928; N = 559). The primary endpoint was progression-free survival (PFS). Results: Overall, 226 patients had received one prior line of therapy. PVd significantly prolonged PFS vs Vd in patients aged ≤65 years (median, 22.0 vs 13.1 months; P =.0258) and. 22022-01-0120222022-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/289540https://dx.doi.org/urn:doi:10.1111/ejh.13706reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2895402026-06-06T12:50:31Z
dc.title.none.fl_str_mv Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma
A subanalysis of OPTIMISMM by clinical characteristics
title Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma
spellingShingle Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma
Richardson, Paul G.|||0000-0002-7426-8865
Aged
Chromosome aberrations
Multiple myeloma
Pomalidomide
Renal insufficiency
title_short Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma
title_full Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma
title_fullStr Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma
title_full_unstemmed Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma
title_sort Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma
dc.creator.none.fl_str_mv Richardson, Paul G.|||0000-0002-7426-8865
Schjesvold, Fredrik|||0000-0003-1096-0569
Weisel, Katja
Moreau, Philippe|||0000-0003-1780-8746
Anderson, Larry D.
White, Darrell
Rodriguez-Otero, Paula|||0000-0001-5236-7785
Sonneveld, Pieter|||0000-0002-0808-2237
Engelhardt, Monika|||0000-0003-0405-1676
Jenner, Matthew
Corso, Alessandro
Dürig, Jan
Pavic, Michel
Salomo, Morten
Beksac, Meral
Oriol, Albert|||0000-0001-6804-2221
Lindsay, Jindriska
Liberati, Anna Marina
Galli, Mónica
Robak, Pawel
Larocca, Alessandra|||0000-0002-2070-3702
Yagci, Munci
Vural, Filiz
Kanate, Abraham
Jiang, Ruiyun
Grote, Lara
Peluso, Teresa
Dimopoulos, Meletios|||0000-0001-8990-3254
author Richardson, Paul G.|||0000-0002-7426-8865
author_facet Richardson, Paul G.|||0000-0002-7426-8865
Schjesvold, Fredrik|||0000-0003-1096-0569
Weisel, Katja
Moreau, Philippe|||0000-0003-1780-8746
Anderson, Larry D.
White, Darrell
Rodriguez-Otero, Paula|||0000-0001-5236-7785
Sonneveld, Pieter|||0000-0002-0808-2237
Engelhardt, Monika|||0000-0003-0405-1676
Jenner, Matthew
Corso, Alessandro
Dürig, Jan
Pavic, Michel
Salomo, Morten
Beksac, Meral
Oriol, Albert|||0000-0001-6804-2221
Lindsay, Jindriska
Liberati, Anna Marina
Galli, Mónica
Robak, Pawel
Larocca, Alessandra|||0000-0002-2070-3702
Yagci, Munci
Vural, Filiz
Kanate, Abraham
Jiang, Ruiyun
Grote, Lara
Peluso, Teresa
Dimopoulos, Meletios|||0000-0001-8990-3254
author_role author
author2 Schjesvold, Fredrik|||0000-0003-1096-0569
Weisel, Katja
Moreau, Philippe|||0000-0003-1780-8746
Anderson, Larry D.
White, Darrell
Rodriguez-Otero, Paula|||0000-0001-5236-7785
Sonneveld, Pieter|||0000-0002-0808-2237
Engelhardt, Monika|||0000-0003-0405-1676
Jenner, Matthew
Corso, Alessandro
Dürig, Jan
Pavic, Michel
Salomo, Morten
Beksac, Meral
Oriol, Albert|||0000-0001-6804-2221
Lindsay, Jindriska
Liberati, Anna Marina
Galli, Mónica
Robak, Pawel
Larocca, Alessandra|||0000-0002-2070-3702
Yagci, Munci
Vural, Filiz
Kanate, Abraham
Jiang, Ruiyun
Grote, Lara
Peluso, Teresa
Dimopoulos, Meletios|||0000-0001-8990-3254
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Aged
Chromosome aberrations
Multiple myeloma
Pomalidomide
Renal insufficiency
topic Aged
Chromosome aberrations
Multiple myeloma
Pomalidomide
Renal insufficiency
description Objective: We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high-risk cytogenetic abnormalities in lenalidomide-pretreated patients with multiple myeloma at first relapse. Methods: OPTIMISMM was a phase 3, multicenter, open-label, randomized study (NCT01734928; N = 559). The primary endpoint was progression-free survival (PFS). Results: Overall, 226 patients had received one prior line of therapy. PVd significantly prolonged PFS vs Vd in patients aged ≤65 years (median, 22.0 vs 13.1 months; P =.0258) and.
publishDate 2022
dc.date.none.fl_str_mv 2
2022-01-01
2022
2022-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/289540
https://dx.doi.org/urn:doi:10.1111/ejh.13706
url https://ddd.uab.cat/record/289540
https://dx.doi.org/urn:doi:10.1111/ejh.13706
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424865666138112
score 15,300719

Similares en LA Referencia